— Know what they know.
Not Investment Advice

IMVT NASDAQ

Immunovant, Inc.
1W: +17.9% 1M: +15.7% 3M: +28.3% YTD: +31.7% 1Y: +127.5% 3Y: +88.6% 5Y: +120.2%
$34.15
+0.02 (+0.06%)
 
Weekly Expected Move ±6.8%
$24 $26 $27 $29 $31
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Buy · Power 66 · $7.0B mcap · 78M float · 2.23% daily turnover · Short 59% of daily vol

Balance Sheet Trends

Total Assets
$957M +23.3% ▲
5Y CAGR: +18.3%
Total Liabilities
$104M +51.8% ▲
5Y CAGR: +37.8%
Shareholders Equity
$853M +20.5% ▲
5Y CAGR: +16.8%
Cash & Investments
$902M +26.4% ▲
5Y CAGR: +17.7%
Total Debt
$72K -26.5% ▼
5Y CAGR: -53.8%
Net Debt
-$902M -26.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2022FY2023FY2024FY2025FY2026
— Assets —
Cash$494M$377M$635M$714M$902M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$494M$377M$635M$714M$902M
Net Receivables$13M$885K$6M$3M$1M
Inventory$0$0$0$0$0
Other Current Assets$0$0$25M$51M$46M
Total Current Assets$513M$404M$666M$768M$949M
Property, Plant & Equip.$3M$2M$595K$942K$515K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$8M$8M
Total Non-Current Assets$3M$2M$942K$9M$8M
Total Assets$516M$406M$667M$776M$957M
— Liabilities —
Accounts Payable$19M$1M$7M$18M$8M
Short-Term Debt$0$0$138K$0$72K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$171K$350K$27M$16M$104M
Total Current Liabilities$45M$43M$49M$69M$104M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$1M$47K$347K$0$0
Total Liabilities$46M$43M$49M$69M$104M
— Equity —
Common Stock$12K$13K$14K$16K$20K
Retained Earnings-$355M-$566M-$826M-$1.2B-$1.7B
Accumulated OCI$404K$852K$2M$1M$730K
Total Stockholders Equity$470M$362M$618M$707M$853M
Total Liabilities & Equity$516M$406M$667M$776M$957M
— Key Metrics —
Total Debt$2M$1M$138K$98K$72K
Net Debt-$491M-$375M-$635M-$714M-$902M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms